Related Experiment Video
Updated: Aug 6, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
Published on: February 1, 2019
A lipid nanoparticle-based oligodendrocyte-specific mRNA therapy
Masanori Sawamura1, Kiyoshi Tachikawa2, Rie Hikawa1
1Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Abstract:
Despite the wide range of applications of mRNA therapies, major difficulties exist in the efficient delivery of mRNA into oligodendrocytes, a type of glial cell in the brain. Commonly used viral vectors are not efficient in transforming oligodendrocytes. In this study, we introduced mRNAs into oligodendrocytes with high efficiency and specificity using LUNAR lipid nanoparticles. The uptake of LUNAR lipid nanoparticles occurred via low-density lipoprotein receptors in the presence of apoprotein E. A single dose of LUNAR-human galactosylceramidase mRNA significantly improved phenotypes and survival of twitcher mice, a mouse model of Krabbe disease wherein oligodendrocytes are damaged by galactosylceramidase deficiency. This approach to mRNA therapeutics, combined with cell-specific nanocarriers, demonstrates remarkable potential for the treatment of neurological disorders associated with oligodendrocytes.
Insights
Researchers developed LUNAR lipid nanoparticles for efficient mRNA delivery into brain oligodendrocytes. This novel method shows promise for treating neurological disorders like Krabbe disease by targeting damaged cells.
Area of Science:
- Neuroscience
- Biotechnology
- Gene Therapy
Background:
- Oligodendrocytes are crucial glial cells in the brain, but efficient mRNA delivery remains a challenge.
- Current viral vectors show limited efficiency in targeting oligodendrocytes for therapeutic interventions.
Purpose of the Study:
- To develop a non-viral method for highly efficient and specific mRNA delivery into oligodendrocytes.
- To evaluate the therapeutic potential of LUNAR lipid nanoparticles for treating oligodendrocyte-related neurological disorders.
Main Methods:
- Utilized LUNAR lipid nanoparticles for mRNA delivery into oligodendrocytes.
- Investigated the uptake mechanism of LUNAR nanoparticles, identifying low-density lipoprotein receptors and apoprotein E involvement.
- Administered LUNAR-human galactosylceramidase mRNA to twitcher mice, a model for Krabbe disease.
Main Results:
- Achieved high efficiency and specificity in delivering mRNA into oligodendrocytes using LUNAR nanoparticles.
- Demonstrated that LUNAR nanoparticle uptake is mediated by low-density lipoprotein receptors in the presence of apoprotein E.
- A single dose of LUNAR-human galactosylceramidase mRNA significantly improved disease phenotypes and survival rates in twitcher mice.
Conclusions:
- LUNAR lipid nanoparticles represent a breakthrough for efficient mRNA delivery into oligodendrocytes.
- This cell-specific nanocarrier approach holds significant potential for developing novel mRNA therapeutics for neurological disorders affecting oligodendrocytes.
- The study highlights a promising strategy for treating Krabbe disease and other myelin disorders.

